Skip to main content
. Author manuscript; available in PMC: 2023 May 23.
Published in final edited form as: Lancet Infect Dis. 2021 Apr 14;21(8):1120–1128. doi: 10.1016/S1473-3099(21)00142-0

Table 2:

Uncorrected and PCR-corrected Kaplan-Meier and per-protocol estimates of artemether–lumefantrine efficacy

Kaplan-Meier
Per protocol
Uncorrected (95% CI) PCR-corrected (95% CI) Uncorrected (95% CI) PCR-corrected (95% CI)

Rukara (n=88) 75·6% (68–85) 94·5% (90–100) 75·6% (65–84) 93·8% (85–98)
Masaka (n=52) 96·0% (91–100) 97·0% (93–100) 96·0% (86–100) 97·0 % (88–100)
Bugarama (n=88) 84·1% (77–92) 97·6% (91–100) 84·1% (75–91) 97·2% (91–100)

Data from follow-up at day 28.